L-Glutamine Therapy for Sickle Cell Anemia and Sickle ß0 Thalassemia

Inclusion Criteria: To be eligible to participate in the study, a patient must meet all of the following inclusion criteria: Patient is at least five years of age. Patient has been diagnosed with sickle cell anemia or sickle ß0-thalassemia (documented by hemoglobin electrophoresis). Patient has had at least two episodes of painful crises within 12 months of the screening visit. If the patient has been treated with an anti-sickling agent within three months of the screening visit, the therapy must have been continuous for at least three months with the intent to continue for the next 14 months. Patient or the patient's legally authorized representative has given written informed consent. If the patient is a female of child-bearing potential, she agrees to practice a recognized form of birth control during the course of the study. Exclusion Criteria: If the patient meets any of the following criteria, the patient must not be enrolled: Patient has a significant medical condition that required hospitalization (other than sickle painful crisis) within two months of the screening visit. Patient has diabetes mellitus with untreated fasting blood sugar >115 mg/dL. Patient has prothrombin time International Normalized Ratio (INR) > 2.0. Patient has serum albumin < 3.0 g/dl. Patient has received any blood products within three weeks of the screening visit. Patient has a history of uncontrolled liver disease or renal insufficiency. Patient is pregnant or lactating. Patient has been treated with an experimental anti-sickling medication/treatment (except hydroxyurea) within 30 days of the screening visit. Patient has been treated with an experimental drug within 30 days of the screening visit. There are factors that would, in the judgment of the investigator, make it difficult for the patient to comply with the requirements of the study.